| Name | Title | Contact Details |
|---|
Diplomat is the nation`s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. We build solutions for today`s issues while laying the groundwork for tomorrow`s healthcare. Rooted in specialty pharmacy, our brands harness innovation to create a healthier world. These include: • Diplomat Specialty Infusion Group: Our specialty infusion services deliver treatments nationwide, but a high-touch approach makes our care personal. • Diplomat Specialty Pharmacy: We help patients across the country face complex and often rare conditions. • CastiaRx: The industry`s leading specialty benefit manager, combining full-service pharmacy benefit manager capabilities with deep specialty expertise. • EnvoyHealth: Firewalled from other Diplomat business, EnvoyHealth is a full-service healthcare solutions company using innovation and technology to help partners improve lives. At Diplomat, we are more than 2,000 professionals working together nationwide to help patients realize health, happiness, and longer, fuller lives. We stand behind our employees with exceptional benefits, continuing education, and award-winning wellness programs. We want this to be the greatest place you`ve ever worked. And we believe it will be.
cenergyteam is a Sammamish, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vita Health Products is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.